Abstract
In Reply. —From a public health perspective, preventing the emergence and transmission of MDR TB in the community through the measures we described is more effective than trying to prevent the development of active TB in those individuals already infected. However, we acknowledge that managing patients infected with isoniazid- and rifampin-resistant strains of Mycobacterium tuberculosis , for which there is no demonstrable effective preventive therapy, is difficult and needs consideration. In answer to Dr Kirkland's questions: First, the CDC's recommendations for the management of persons exposed to MDR TB have not changed since their 1992 publication. 1 We continue to strongly recommend alternative preventive therapy (ie, multidrug regimens with drugs other than isoniazid or rifampin) for contacts of MDR TB patients who have (1) a high likelihood of having been infected with the drugresistant M tuberculosis strain and (2) a high likelihood of progressing to active TB. The possibility of preventive therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
